What Is Tirzepatide? Uses, Risks, and FDA Status
What Is Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. It is FDA-approved under the brand names Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). Unlike semaglutide, which targets only GLP-1 receptors, tirzepatide activates both GIP and GLP-1 pathways, which research suggests may produce greater metabolic effects.
How Does Tirzepatide Work?
Tirzepatide simultaneously activates two incretin hormone receptors. The GLP-1 receptor activation stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite — similar to semaglutide. The GIP (glucose-dependent insulinotropic polypeptide) receptor activation adds additional insulin-stimulating effects and may improve fat metabolism. The dual mechanism appears to produce more pronounced effects on both blood sugar control and weight loss than GLP-1-only agents. Like semaglutide, it is administered as a once-weekly subcutaneous injection.
What Is Tirzepatide Used For?
- Type 2 diabetes — FDA-approved (Mounjaro) for blood sugar control; the SURPASS trials showed superior A1C reduction compared to semaglutide (Frías et al., N Engl J Med, 2021)
- Chronic weight management — FDA-approved (Zepbound) for adults with obesity or overweight with comorbidities; the SURMOUNT-1 trial showed up to 22.5% body weight reduction at the highest dose (Jastreboff et al., N Engl J Med, 2022)
- Obstructive sleep apnea — FDA-approved for moderate-to-severe OSA in adults with obesity
- Heart failure with preserved ejection fraction (HFpEF) — Under investigation
- NASH/MASH — Under investigation for liver disease
What Are the Risks?
- Gastrointestinal side effects. Nausea, diarrhea, vomiting, and constipation are common, especially during dose titration. These typically improve over time.
- Pancreatitis. Cases have been reported in clinical trials. Patients with a history of pancreatitis should discuss risks with their provider.
- Thyroid risk. Like semaglutide, tirzepatide carries a boxed warning for thyroid C-cell tumors based on animal data. Contraindicated in patients with MTC or MEN 2 history.
- Hypoglycemia. Risk increases when combined with insulin or sulfonylureas.
- Gallbladder events. Increased incidence of gallstones observed in clinical trials.
- Injection site reactions. Redness, itching, or swelling at the injection site have been reported.
FDA Status
Tirzepatide is FDA-approved as a branded pharmaceutical (Mounjaro, Zepbound). Compounded versions have been available through pharmacies during branded drug shortages. As with semaglutide, the regulatory status of compounded tirzepatide depends on current FDA shortage designations and is subject to change. Eli Lilly has actively pursued legal action against some compounding pharmacies.
Key Takeaway
Tirzepatide is an FDA-approved dual-action incretin mimetic with the strongest weight loss data of any approved medication to date, though it shares a similar side effect profile with other GLP-1 class drugs.
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.